183 related articles for article (PubMed ID: 29103138)
1. A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.
Kaito S; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y; Hishima T; Maeda Y
Int J Hematol; 2018 Apr; 107(4):451-459. PubMed ID: 29103138
[TBL] [Abstract][Full Text] [Related]
2. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified.
Beltran BE; Aguilar C; Quiñones P; Morales D; Chavez JC; Sotomayor EM; Castillo JJ
Leuk Lymphoma; 2016; 57(1):58-62. PubMed ID: 25926063
[TBL] [Abstract][Full Text] [Related]
3. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
[TBL] [Abstract][Full Text] [Related]
4. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T-cell lymphoma presenting as secondary myelofibrosis with high levels of PDGF and TGF-beta.
Abe Y; Ohshima K; Shiratsuchi M; Honda K; Nishimura J; Nawata H; Muta K
Eur J Haematol; 2001 Mar; 66(3):210-2. PubMed ID: 11350491
[No Abstract] [Full Text] [Related]
6. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
[TBL] [Abstract][Full Text] [Related]
8. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
9. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.
Yi JH; Kim JH; Baek KK; Lim T; Lee DJ; Ahn YC; Kim K; Kim SJ; Ko YH; Kim WS
Ann Oncol; 2011 Jul; 22(7):1636-1643. PubMed ID: 21220520
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification.
Kim K; Kim WS; Jung CW; Im YH; Kang WK; Lee MH; Park CH; Ko YH; Ree HJ; Park K
Eur J Cancer; 2002 Jan; 38(1):75-81. PubMed ID: 11750843
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Qin Y; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Liu XF; Liu P; Yang S; Zhou LQ; Han XH; Yao JR
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):448-51. PubMed ID: 20819488
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
14. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
[TBL] [Abstract][Full Text] [Related]
15. [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].
Huang HQ; Peng YL; Lin XB; Sun XF; Lin TY; Xia ZJ; Li YH; Cai QQ; He YJ; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1443-7. PubMed ID: 15566653
[TBL] [Abstract][Full Text] [Related]
16. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
Chihara D; Oki Y; Ine S; Yamamoto K; Kato H; Taji H; Kagami Y; Yatabe Y; Nakamura S; Morishima Y
Leuk Lymphoma; 2009 Dec; 50(12):1999-2004. PubMed ID: 19860627
[TBL] [Abstract][Full Text] [Related]
17. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
18. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Shiratori S; Kosugi-Kanaya M; Shigematsu A; Kobayashi H; Yamamoto S; Kobayashi N; Iwasaki H; Mori A; Kunieda Y; Yutaka T; Kurosawa M; Kakinoki Y; Endo T; Kondo T; Hashino S; Teshima T;
Leuk Lymphoma; 2015; 56(9):2592-7. PubMed ID: 25563559
[TBL] [Abstract][Full Text] [Related]
19. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
